Tarsus Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$76.24(as of Mar 4, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Tarsus Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$76.24
Ticker SymbolTARS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees370
CountyUSA
Market Cap$3,257.8M
EBIDTA-69.2M
10-Day Moving Average73.10
P/E Ratio-49.09
20-Day Moving Average68.40
Forward P/E Ratio106.38
50-Day Moving Average72.27
Earnings per Share-1.59
200-Day Moving Average60.76
Profit Margin-5.52%
RSI62.37
Shares Outstanding42.6M
ATR3.80
52-Week High85.25
Volume255,526
52-Week Low38.51
Most Recent Support Level73.08
Book Value343.4M
Most Recent Resistance Level77.75
P/B Ratio9.49
Upper Keltner76.95
P/S Ratio7.22
Lower Keltner59.84
Debt-to-Equity Ratio76.95
Next Earnings Date03/16/2026
Cash Surplus47.9M
Next Ex-Dividend DateUnknown

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tarsus Pharmaceuticals Inc In Our Stock Scanner

As of Mar 04, 2026
example chart graphic
Scan Name: WedgeScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.